Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Abstract

Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).

Keywords

MedicineT790MLung cancerInternal medicineEpidermal growth factor receptorAdverse effectPharmacokineticsOncologyCancerEGFR inhibitorsPharmacologyGastroenterologyGefitinib

MeSH Terms

AcrylamidesAgedAntineoplastic AgentsCarcinomaNon-Small-Cell LungDose-Response RelationshipDrugDrug ResistanceNeoplasmErbB ReceptorsFemaleHumansHyperglycemiaLung NeoplasmsMaleMiddle AgedMutationProtein Kinase InhibitorsPyrimidines

Affiliated Institutions

Related Publications

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

Lecia V. Sequist , Renato Martins , David R. Spigel +16 more

Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR ...

2008 Journal of Clinical Oncology 829 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez , Pasi A. Jänne , Jeffrey C. Lee +14 more

Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGF...

2004 Science 9327 citations

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Suresh S. Ramalingam , Johan Vansteenkiste , David Planchard +21 more

Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a compar...

2019 New England Journal of Medicine 2577 citations

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti , Sugandhi Sharma , Roberta Minari +3 more

Abstract Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR- activating mutatio...

2019 British Journal of Cancer 1233 citations

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

Akira Inoue , Takuji Suzuki , Tatsuro Fukuhara +6 more

Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) h...

2006 Journal of Clinical Oncology 503 citations

Publication Info

Year: 2015
Type: article
Volume: 372
Issue: 18
Pages: 1700-1709
Citations: 658
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

658

OpenAlex

Influential

527

CrossRef

Cite This

APA Style

                            
                                
                                    Lecia V. Sequist, 
                                
                                    Jean‐Charles Soria, 
                                
                                    Jonathan W. Goldman
                                
                                et al.
                            
                            (2015). 
                            Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer. 
                            New England Journal of Medicine
                            , 372
                            (18)
                            , 1700-1709.
                            https://doi.org/10.1056/nejmoa1413654
                        

Identifiers

DOI: 10.1056/nejmoa1413654
PMID: 25923550

Data Quality

Data completeness: 86%

Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer